BI-3812 is a selective and potent inhibitor of the enzyme soluble epoxide hydrolase (sEH). This compound is primarily used in preclinical research to study inflammatory pathways and pain modulation. By inhibiting sEH, BI-3812 increases the levels of endogenous epoxy fatty acids, which have anti-inflammatory, analgesic, and vasodilatory effects. It has shown promise in models of neuropathic pain, where it reduces hypersensitivity and inflammation without significant CNS side effects. Its high selectivity and favorable pharmacokinetic profile make it a valuable tool compound for validating sEH as a therapeutic target in chronic pain, neuroinflammation, and related conditions. Researchers also use BI-3812 to explore potential applications in cardiovascular and metabolic diseases where inflammation plays a key role.